179 related articles for article (PubMed ID: 11332317)
21. [Adjuvant tamoxifen treatment in breast cancer: is 5-year treatment sufficient?].
Andersson M; Dombernowsky P
Ugeskr Laeger; 1997 Jun; 159(25):3968-9. PubMed ID: 9214074
[No Abstract] [Full Text] [Related]
22. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
24. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
25. [Advances and perspective in clinical research on breast cancer].
Xu BH
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):881-3. PubMed ID: 18478923
[No Abstract] [Full Text] [Related]
26. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
27. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Pritchard KI
J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
[No Abstract] [Full Text] [Related]
28. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen for patients with estrogen receptor-negative breast cancer.
Swain SM
J Clin Oncol; 2001 Sep; 19(18 Suppl):93S-97S. PubMed ID: 11560981
[No Abstract] [Full Text] [Related]
30. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
31. [Hormonal therapy in breast cancer].
Espinós J; Reyna C; de la Cruz S; Oiler C; Hernández A; Fernández Hidalgo O; Santisteban M; García Foncillas J
Rev Med Univ Navarra; 2008; 52(1):40-8. PubMed ID: 18578196
[TBL] [Abstract][Full Text] [Related]
32. The patterns of care study for breast-conserving therapy in Japan: analysis of process survey from 1995 to 1997.
Mitsumori M; Hiraoka M; Negoro Y; Yamauchi C; Shikama N; Sasaki S; Yamamoto T; Teshima T; Inoue T
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1048-54. PubMed ID: 15990008
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cm.
Russell CA
Curr Womens Health Rep; 2002 Apr; 2(2):134-9. PubMed ID: 12116603
[TBL] [Abstract][Full Text] [Related]
34. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
[TBL] [Abstract][Full Text] [Related]
35. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
36. Update: NCCN breast cancer Clinical Practice Guidelines.
Carlson RW; McCormick B
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S7-11. PubMed ID: 16280118
[No Abstract] [Full Text] [Related]
37. Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
Oncology (Williston Park); 2005 Mar; 19(3):277, 360. PubMed ID: 15828547
[No Abstract] [Full Text] [Related]
38. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Schwartzberg LS; Cobb P; Senecal F; Henry D; Kulig K; Walker MS; Houts AC; Stepanski EJ
Breast; 2009 Apr; 18(2):78-83. PubMed ID: 19342237
[TBL] [Abstract][Full Text] [Related]
39. Tumoristatic action of tamoxifen: experimental evidence for clinical application in stage I and II breast cancer.
Jordan VC
J Chemother; 1989 Jul; 1(4 Suppl):1144-7. PubMed ID: 16312810
[No Abstract] [Full Text] [Related]
40. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
